Extended Data Fig. 6: Forest plots for ICB cohorts with >100 samples.
From: MHC II immunogenicity shapes the neoepitope landscape in human tumors
The hazard ratio predicted by each neoantigen prediction method was plotted for a, our cohort in lung cancer, b, Mariathasan cohort in bladder cancer, and c, Van Allen cohort in melanoma. High immunogenic neoantigen load predicted by DeepNeo class II demonstrated the lowest hazard ratio, indicating the highest correlation of predicted neoantigen load with the survival outcome.
